Amyotrophic Lateral Sclerosis Clinical Trials in Philadelphia, Pennsylvania

6 studies are recruiting for amyotrophic lateral sclerosis in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

   The goal of this clinical trial is to learn if the drug pridopidine works to treat amyotrophic lateral sclerosis in adults. It will also help to learn about the safety of pridopidine. The main question it aims to answer is: Does pridopidine slow disease progression of ALS? Researchers will compare …

   Stage

   Phase 3

   Ages

   18 to 80

   Site

   Neuroscience Department at LKSM at Temple University, Philadelphia, Pennsylvania

   Locations

   55 in total

   Run by

   Prilenia

   See if you can join NCT07322003 on ClinicalTrials.gov

2. Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

   PIONEER-ALS is a Phase 1/2, multicenter, open-label, ascending dose, uncontrolled, first-in-human study that will evaluate the safety, tolerability and effects on clinical and biomarker endpoints of intracisternal administration of Vtx-002 in participants with Amyotrophic Lateral Sclerosis (ALS). T…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   11 in total

   Run by

   Vector Y Therapeutics

   See if you can join NCT07287397 on ClinicalTrials.gov

3. A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)

   The primary objective of this dose-finding study is to evaluate the safety, tolerability and pharmacodynamics of single dose of INS1202 via IT administration in participants ≥ 18 to <80 years of age with ALS who carry superoxide dismutase type 1 (SOD1) mutations or harbor no known ALS-related genet…

   Stage

   Phase 1

   Ages

   18 to 79

   Site

   USA006, Philadelphia, Pennsylvania

   Locations

   7 in total

   Run by

   Insmed Gene Therapy LLC

   See if you can join NCT07290062 on ClinicalTrials.gov

4. ASSESS ALL ALS Study

   The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is being funded by the National Institutes of Heal…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   37 in total

   Run by

   St. Joseph's Hospital and Medical Center, Phoenix

   See if you can join NCT06578195 on ClinicalTrials.gov

5. PREVENT ALL ALS Study

   The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is begin funded by the National Institutes of Heal…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Temple University, Philadelphia, Pennsylvania

   Locations

   32 in total

   Run by

   St. Joseph's Hospital and Medical Center, Phoenix

   See if you can join NCT06581861 on ClinicalTrials.gov

6. ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

   ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   27 in total

   Run by

   Mayo Clinic

   See if you can join NCT04363684 on ClinicalTrials.gov